Vitamin K epoxide reductase (VKORC1)
Clinical / pharmacological. Warfarin target; VKORC1 genotype drives dose variability
What it does, reaction by reaction
Vitamin K Cycle Cofactor & Vitamin Metabolism · ER membrane
Vitamin K 2,3-epoxide -> vitamin K quinone
Converts Vitamin K 2,3-epoxide into Vitamin K quinone
› Notes
The warfarin target. VKORC1 polymorphisms are a major determinant of warfarin dose requirement.
Showing all 1 reactions.
What accelerates and inhibits it
Regulation is pathway-specific, so each context is listed separately
No regulation recorded for this enzyme in the source documents.
Recent literature
Europe PMC · fetched just now · sorted by publication date
-
1
Natural products targeting hepatitis B virus X protein and HBx-associated pathways in HBV-related hepatocellular carcinoma: mechanisms and therapeutic potential.
Nguyen TNA, Thongsri P, Pewkliang Y, Chomnawang MT, Thirapanmethee K, Sa-Ngiamsuntorn K. · 2026-09-04
open access unreviewed -
2
Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment.
García-López A, Antonio AG, Rubio-Lepe TS, Diago-Sempere E, Raffo-Nogueira J, Arias P, Ferrer-Martínez B, Rod… · 2026-11-01
unreviewed -
3
From Genomics to Precision Cardiology: A Comprehensive Review of Clinical Applications and Challenges in Cardiovascular Diseases.
Mohsen-Pour N, Esmaeili S, Feyzi A, Sharafi A, Maleki M, Kalayinia S. · 2026-10-01
open access unreviewed -
4
γ-glutamyl carboxylase inhibition by Anisindione.
Zhou N, Wang R, Chen B, Li J, Tie JK, Liu F, Qi X. · 2026-08-27
unreviewed -
5
Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine.
Rogić D, Šimičević L, Žigman T, Bambir I, Vukić Dugac A, Tješić-Drinković D, Fumić K, Lehman I, Rako I, Popov… · 2026-08-10
open access unreviewed -
6
Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models.
Sridharan K, Sivaramakrishnan G, Santoni M. · 2026-06-02
unreviewed -
7
CardioPharmaGENET (CA24165): A COST action network for advancing cardiovascular pharmacogenomics and precision medicine
Ašić A, Devaux Y, Sopić M, Jusić A, Spahić L, Vitorino R, Marjanović D, Tashkov K, Katsila T, Džuho A, Karađu… · 2026-09-23
open access unreviewed -
8
Machine Learning-Directed Explainable Artificial Intelligence and Bayesian Predictions of Warfarin Therapeutic Dose for Orthopedic Indications.
Sridharan K, Sivaramakrishnan G. · 2026-09-25
unreviewed -
9
Mapping Pharmacogenomic Determinants of Adverse Drug Reactions in Hypertension: A Systematic Review.
Dsouza VS, Kurian JR, Kalita M, Bora K, Phukan S, Das R, Bhowmick IP. · 2026-09-18
open access unreviewed -
10
Association of Native American, European, and African Ancestry with CYP450 Pharmacogenetics and Metabolic Phenotypes in Admixed Latin American Populations from Ecuador and Nicaragua.
de la Cruz CG, Altamirano-Tinoco C, Manóchio C, Villatoro-García JA, de Andrés F, Mata-Martín C, Rodrigues-So… · 2026-09-10
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.